CPSF3L Inhibitors

The chemical class 'CPSF3L Inhibitors' comprises a range of compounds selected for their potential to modulate the functions or interactions of CPSF3L within the Integrator complex. These inhibitors target various aspects of transcription and RNA processing, with a focus on disrupting RNA polymerase II activities and influencing RNA splicing and processing mechanisms. Compounds like Triptolide, α-Amanitin, and DRB directly target RNA polymerase II, which is crucial for the transcription of snRNAs and the functioning of the Integrator complex, including CPSF3L. By inhibiting RNA polymerase II or its phosphorylation, these compounds can indirectly affect the 3'-end processing of snRNAs, a key role of CPSF3L. Flavopiridol and Roscovitine inhibit cyclin-dependent kinases that regulate RNA polymerase II, potentially impacting transcription processes involving CPSF3L. Actinomycin D, by binding to DNA and inhibiting RNA synthesis, can also indirectly influence CPSF3L's function in RNA processing.

Inhibitors like Pladienolide B target the spliceosome, which is involved in RNA processing, potentially affecting the function of CPSF3L in snRNA processing. Additionally, compounds like Ispinesib, BX 795, and THZ1 are included for their broader impact on cellular functions that may intersect with the role of CPSF3L in the Integrator complex. CAY10683 and Rocaglamide, targeting the HIF pathway and eukaryotic initiation factor 4A (eIF4A) respectively, provide insights into how altering transcription and translation processes can indirectly influence CPSF3L's function. In summary, the 'CPSF3L Inhibitors' encompass various compounds aimed at modulating the transcriptional and RNA processing activities associated with CPSF3L within the Integrator complex. By targeting key enzymes and processes in RNA synthesis and processing, these inhibitors serve as valuable tools for investigating the functions of CPSF3L and its role in the Integrator complex in cellular contexts.